A pivotal study of Brilacidin for Oral Mucositis
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Brilacidin (Primary)
- Indications Stomatitis
- Focus Registrational; Therapeutic Use
- Sponsors Innovation Pharmaceuticals
- 02 Jan 2019 According to an Innovation Pharmaceuticals media release, the company expects to initiate this study in 2019.
- 17 Dec 2018 According to a media release, the company and the US FDA have completed an End-of-Phase 2 meeting concerning the continuing development of Brilacidin oral rinse to decrease the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
- 23 Nov 2018 New trial record